Bristol Myers Squibb’S Supplemental New Drug Application (SNDA) For Sotyktu (Deucravacitinib) Accepted for Review Across Four Regions

July 21 (Reuters) - Bristol-Myers Squibb Co BMY.N:

• BRISTOL MYERS SQUIBB’S SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR SOTYKTU (DEUCRAVACITINIB) FOR THE TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS ACCEPTED FOR REVIEW ACROSS FOUR REGIONS GLOBALLY

• BRISTOL-MYERS SQUIBB CO - FDA TARGET ACTION DATE FOR SOTYKTU SET FOR MARCH 6, 2026